Hana Biosciences - Worst Pharma Stocks of 2007

Company: Hana Biosciences
Starting stock price: $5.94
Ending stock price: $1.06
Percent Change: -82.15%

Details: Hana Biosciences is a South San Francisco company focused on cancer treatments. It has two compounds in clinical trials and others in preclinical development. In August 2007, its its Marqibo product was fast-tracked by the FDA for use in leukemia patients suffering their second relapse. In October, it announced $30 million in financing from Deerfield Management.

More News:
Hana gains $30M credit line to back discovery work. Report
Hana gains orphan drug status. Report
FDA to review Hana nausea therapy. Report

Hana Biosciences - Worst Pharma Stocks of 2007

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.